Marksans Pharma Limited (NSE:MARKSANS)
India · Delayed Price · Currency is INR | Market Cap | 105.67B -3.4% |
| Revenue (ttm) | 29.51B +12.5% |
| Net Income | 4.18B +9.8% |
| EPS | 9.22 +9.8% |
| Shares Out | 453.16M |
| PE Ratio | 25.29 |
| Forward PE | 19.68 |
| Dividend | 0.90 (0.39%) |
| Ex-Dividend Date | Aug 1, 2025 |
| Volume | 1,734,134 |
| Open | 240.90 |
| Previous Close | 239.14 |
| Day's Range | 230.50 - 244.42 |
| 52-Week Range | 155.00 - 270.70 |
| Beta | 1.10 |
| Analysts | Strong Buy |
| Price Target | 266.00 (+13.92%) |
| Earnings Date | May 26, 2026 |
About Marksans Pharma
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, an... [Read more]
Financial Performance
In fiscal year 2026, Marksans Pharma's revenue was 29.51 billion, an increase of 12.51% compared to the previous year's 26.23 billion. Earnings were 4.18 billion, an increase of 9.81%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MARKSANS stock is "Strong Buy." The 12-month stock price target is ₹266.00, which is an increase of 13.92% from the latest price.
News
Marksans Pharma launches 'Saksham Niveshak' campaign to address unclaimed dividends
Marksans Pharma has initiated a 'Saksham Niveshak' campaign aimed at assisting shareholders in claiming unclaimed dividends from the financial year 2018-19 onwards. This initiative is in response to a...
Marksans Pharma to acquire Netherlands-based QliniQ B.V. to expand presence in European markets
Marksans Pharma Ltd has announced that it has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a Netherlands-based pharmaceutical company with established sales...
Marksans Pharma Transcript: Q4 25/26
Record FY 2026 results with net income above INR 3,000 crore, strong growth in North America, and margin expansion. Guidance targets INR 4,000 crore revenue by FY 2028, with robust product pipeline and ongoing M&A focus.
Marksans Pharma Quarterly report: Q4 2026
Marksans Pharma has published its Q4 2026 quarterly earnings report on May 27, 2026.
Marksans Pharma Slides: Q4 2026
Marksans Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 27, 2026.
Marksans Pharma reports highest-ever revenue of Rs 3,033 crore for FY26
Marksans Pharma Ltd. has announced its financial results for the fiscal year ending March 31, 2026, achieving a record total income of ₹3,033 crore. This marks a 12.8% increase compared…
Marksans Pharma Q4 Results: Net profit jumps 64% as EBITDA margin expands sharply
Marksans Pharma reported a strong set of quarterly earnings for the March 2026 quarter, driven by healthy revenue growth and significant improvement in operating profitability. The company’s consolida...
Marksans Pharma receives USFDA approval for Benzonatate Capsules
Marksans Pharma Limited has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP, available in 100 mg…
Pharma sector stocks rally sharply today, April 1: Marksans Pharma jumps 6%, Alembic gains 5.37%, Glenmark Pharma surge 4.30%
Indian pharma stocks showed broad-based gains in early trading on April 1, 2026. Many companies in the sector traded higher on both BSE and NSE, even as the broader market…
Pharma sector stocks today, Feb 9: Marksans Pharma up 5%, Shilpa Medicare jumps 6%, Glenmark rises 1.83%
The Indian pharma sector showed mixed intraday movements on February 9, 2026, amid broader market gains driven by positive global...
Marksans Pharma Transcript: Q3 25/26
Q3 FY26 saw record revenue and margin expansion, led by strong U.S. growth and stabilization in the U.K. New product launches, robust order book, and strategic expansion in Europe and Canada support a positive outlook, with INR 4,000 crore revenue targeted in 2-3 years.
Marksans Pharma Quarterly report: Q3 2026
Marksans Pharma has published its Q3 2026 quarterly earnings report on February 6, 2026.
Marksans Pharma Slides: Q3 2026
Marksans Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 6, 2026.
Pharma sector stocks today, Feb 6: Concord Biotech jumps 4.61%, Alembic Pharma falls 4%, Marksans Pharma down 3.48%
The Indian pharmaceutical sector displayed mixed performance in early trading on February 6, 2026, as of approximately 10:00 AM IST....
Marksans Pharma gets final USFDA approval for Loperamide Hydrochloride Tablets
Marksans Pharma Limited has received the final approval for the Abbreviated New Drug Application filed by its wholly owned US...
Marksans Pharma secures UK MHRA approval for 250 mg and 500 mg Mefenamic Acid
Marksans Pharma has announced that its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorization from the UK’s Medicines...
Marksans Pharma Transcript: Q2 25/26
Q2 FY 2026 delivered strong sequential and year-on-year growth, with revenue up 16% QoQ and 12.2% YoY, driven by robust U.S. and U.K. performance, new product launches, and operational efficiencies. Tariff uncertainties have eased, supporting a positive outlook and continued expansion in Europe.
Marksans Pharma Quarterly report: Q2 2026
Marksans Pharma has published its Q2 2026 quarterly earnings report on November 14, 2025.
Marksans Pharma Slides: Q2 2026
Marksans Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 14, 2025.
Marksans Pharma’s Goa facility clears US FDA inspection with zero observations
Marksans Pharma Limited announced that its second manufacturing facility in Verna, Goa, successfully completed a current Good Manufacturing Practice (cGMP)...
Marksans Pharma shares rise after UK MHRA approval for cancer drug Exemestane 25mg tablets
Shares of Marksans Pharma Ltd gained 1.24% to Rs 189.11 in Thursday’s trade after the company announced that its UK-based...
Marksans Pharma’s UK subsidiary Relonchem gets MHRA approval for Exemestane 25mg Tablets
Marksans Pharma Limited announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK’s Medicines...
Marksans Pharma’s UK subsidiary Relonchem secures MHRA approval for two products
Marksans Pharma Limited announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK’s Medicines...
Marksans Pharma shares fall over 3.5% after Trump’s 100% tariff announcement on pharma imports
Shares of Marksans Pharma Ltd dropped 3.6% to ₹163.30 in Friday’s session, reacting to U.S. President Donald Trump’s announcement of a 100% tariff on branded and patented pharmaceutical imports, effec...
Marksans Pharma’s UK Subsidiary Relonchem secures marketing authorization for Moxonidine tablets from UK MHRA
Marksans Pharma Limited, a Mumbai-headquartered global pharmaceutical company, announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medici...